Key Points
- Director Robert Chess sold 10,000 shares on March 17 at an average price of $47 for $470,000, reducing his stake by 32.17% to 21,084 shares; the sale was disclosed in an SEC filing.
- Twist reported Q4 EPS of -$0.50 (missed estimates) with revenue of $103.7M (up 16.9% YoY) and trades with a market cap of about $2.75B, reflecting continued unprofitability.
- Analyst sentiment is mixed-to-positive: the consensus is a Moderate Buy (7 Buys vs. 2 Sells) with an average target of $45.88, and several firms have raised targets into the $50–$52 range.
Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) Director Robert Chess sold 10,000 shares of the business's stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total transaction of $470,000.00. Following the transaction, the director owned 21,084 shares in the company, valued at approximately $990,948. The trade was a 32.17% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Twist Bioscience Stock Performance
NASDAQ TWST opened at $44.80 on Friday. The firm has a market capitalization of $2.75 billion, a P/E ratio of -35.00 and a beta of 2.23. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. The firm's fifty day moving average price is $45.72 and its two-hundred day moving average price is $35.68. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $57.88.
Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.02). The firm had revenue of $103.70 million during the quarter, compared to the consensus estimate of $100.32 million. Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. Twist Bioscience's revenue was up 16.9% on a year-over-year basis. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.
Institutional Investors Weigh In On Twist Bioscience
Hedge funds have recently bought and sold shares of the stock. Quarry LP bought a new stake in shares of Twist Bioscience during the third quarter worth approximately $28,000. Smartleaf Asset Management LLC increased its stake in shares of Twist Bioscience by 70.6% during the third quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company's stock worth $29,000 after purchasing an additional 442 shares during the period. Strategic Advocates LLC lifted its holdings in Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company's stock worth $34,000 after purchasing an additional 906 shares during the last quarter. SBI Securities Co. Ltd. lifted its holdings in Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company's stock worth $44,000 after purchasing an additional 571 shares during the last quarter. Finally, National Bank of Canada FI bought a new stake in Twist Bioscience in the 3rd quarter valued at $46,000.
Analysts Set New Price Targets
TWST has been the topic of a number of recent analyst reports. TD Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a research note on Monday, December 29th. Robert W. Baird set a $50.00 target price on Twist Bioscience in a report on Tuesday, February 3rd. Evercore increased their price target on Twist Bioscience from $42.00 to $52.00 and gave the company an "outperform" rating in a research note on Tuesday, February 3rd. Finally, Barclays raised their price target on Twist Bioscience from $39.00 to $50.00 and gave the company an "overweight" rating in a report on Tuesday, February 3rd. Seven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $45.88.
Get Our Latest Analysis on Twist Bioscience
About Twist Bioscience
(
Get Free Report)
Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.
At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
